GS Investments Inc. Has $2.86 Million Stake in Amgen Inc. (NASDAQ:AMGN)

GS Investments Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 3.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,957 shares of the medical research company’s stock after selling 426 shares during the quarter. GS Investments Inc.’s holdings in Amgen were worth $2,856,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AMGN. Royal London Asset Management Ltd. boosted its position in Amgen by 0.6% during the 4th quarter. Royal London Asset Management Ltd. now owns 230,790 shares of the medical research company’s stock worth $60,153,000 after acquiring an additional 1,424 shares during the last quarter. First Financial Bankshares Inc lifted its position in shares of Amgen by 2.0% in the fourth quarter. First Financial Bankshares Inc now owns 229,053 shares of the medical research company’s stock worth $59,700,000 after purchasing an additional 4,476 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in Amgen during the fourth quarter worth $1,669,000. Investment House LLC grew its position in Amgen by 2.7% in the fourth quarter. Investment House LLC now owns 35,531 shares of the medical research company’s stock valued at $9,261,000 after purchasing an additional 950 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd increased its stake in Amgen by 15.1% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 31,657 shares of the medical research company’s stock valued at $8,199,000 after buying an additional 4,161 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $315.75 on Thursday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The firm has a market capitalization of $169.62 billion, a P/E ratio of 41.82, a P/E/G ratio of 2.63 and a beta of 0.53. The firm’s 50-day moving average price is $295.15 and its 200-day moving average price is $299.03. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.02%. Amgen’s payout ratio is 126.09%.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Finally, Redburn Partners dropped their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.